Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete

MT Newswires Live06-05

Fusion Pharmaceuticals (FUSN) said late Tuesday its $2.4 billion acquisition by an AstraZeneca (AZN) subsidiary was completed.

The deal "marks a major step forward" in AstraZeneca's ambition to transform cancer treatment by replacing traditional regimens of chemotherapy and radiotherapy with more targeted treatments, Fusion said.

The AstraZeneca unit paid $21 a share in cash plus a non-transferable contingent value right of $3 a share in cash payable on achieving a specified regulatory milestone before Aug. 31, 2029, representing the transaction value of $2.4 billion, Fusion said.

AstraZeneca acquired the cash, cash equivalents and short-term investments on Fusion's balance sheet, which totaled $211 million as of March 31.

Price: 21.70, Change: +0.15, Percent Change: +0.70

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441263139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-05 05:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2441263139","market":"sg","top_or_hot":-1,"title":"Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete","media":"MT Newswires Live","content":"<html><body><p> Fusion Pharmaceuticals (FUSN) said late Tuesday its $2.4 billion acquisition by an AstraZeneca (AZN) subsidiary was completed.</p><p>The deal \"marks a major step forward\" in AstraZeneca's ambition to transform cancer treatment by replacing traditional regimens of chemotherapy and radiotherapy with more targeted treatments, Fusion said.</p><p>The AstraZeneca unit paid $21 a share in cash plus a non-transferable contingent value right of $3 a share in cash payable on achieving a specified regulatory milestone before Aug. 31, 2029, representing the transaction value of $2.4 billion, Fusion said.</p><p>AstraZeneca acquired the cash, cash equivalents and short-term investments on Fusion's balance sheet, which totaled $211 million as of March 31.</p><p>Price: 21.70, Change: +0.15, Percent Change: +0.70</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-05 05:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fusion Pharmaceuticals (FUSN) said late Tuesday its $2.4 billion acquisition by an AstraZeneca (AZN) subsidiary was completed.The deal \"marks a major step forward\" in AstraZeneca's ambition to ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2441263139","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441263139","pubTimestamp":1717535594,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Fusion Pharmaceuticals  said late Tuesday its $2.4 billion acquisition by an AstraZeneca  subsidiary was completed.The deal \"marks a major step forward\" in AstraZeneca's ambition to transform cancer treatment by replacing traditional regimens of chemotherapy and radiotherapy with more targeted treatments, Fusion said.The AstraZeneca unit paid $21 a share in cash plus a non-transferable contingent value right of $3 a share in cash payable on achieving a specified regulatory milestone before Aug. 31, 2029, representing the transaction value of $2.4 billion, Fusion said.AstraZeneca acquired the cash, cash equivalents and short-term investments on Fusion's balance sheet, which totaled $211 million as of March 31.Price: 21.70, Change: +0.15, Percent Change: +0.70","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康","BK4139":"生物科技","BK4568":"美国抗疫概念","FUSN":"Fusion Pharmaceuticals Inc.","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4007":"制药","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念"},"translate_title":"Fusion Pharmaceuticals表示阿斯利康子公司24亿美元收购已完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FUSN":1,"AZN":0.9},"content_text":"Fusion Pharmaceuticals (FUSN) said late Tuesday its $2.4 billion acquisition by an AstraZeneca (AZN) subsidiary was completed.The deal \"marks a major step forward\" in AstraZeneca's ambition to transform cancer treatment by replacing traditional regimens of chemotherapy and radiotherapy with more targeted treatments, Fusion said.The AstraZeneca unit paid $21 a share in cash plus a non-transferable contingent value right of $3 a share in cash payable on achieving a specified regulatory milestone before Aug. 31, 2029, representing the transaction value of $2.4 billion, Fusion said.AstraZeneca acquired the cash, cash equivalents and short-term investments on Fusion's balance sheet, which totaled $211 million as of March 31.Price: 21.70, Change: +0.15, Percent Change: +0.70","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441263139"}